Vectura wins IND for drug-device combo for pediatric asthma

Vectura said yesterday that the FDA approved an Investigational New Device application for its drug-device combination to treat asthma in children 12 months to 8 years old. The UK-based company’s device, VR647, uses the Akita Jet nebulizer for the delivery of nebulized budesonide.

Vectura’s drug-device combination product provides faster delivery time and better lung deposition of budesonide, according to the company, and enables a patient to potentially lower their dosage while maintaining efficacy.

Get the full story at our sister site, Drug Delivery Business News.

The post Vectura wins IND for drug-device combo for pediatric asthma appeared first on MassDevice.

from MassDevice http://ift.tt/2jZBaSJ